FDA Infant Formula Regulation — Nutrient Standards, Safety, and Recall

Infant formula is one of the most tightly regulated food products in the United States. For infants who are not breastfed, commercial formula may be their sole source of nutrition for the first six months of life — a fact that drives a regulatory regime uniquely focused on nutrient completeness, manufacturing safety, and market surveillance. 21 CFR Part 107 implements the Infant Formula Act of 1980 (as amended by FDCA § 412, codified at 21 U.S.C. § 350a), which gives FDA authority to set minimum and maximum nutrient levels, require pre-market notification for new formulas, mandate recall authority, and require rigorous records retention throughout the supply chain. The 2022 Abbott Similac recall — triggered by Cronobacter sakazakii contamination that sickened four infants and killed two — exposed critical vulnerabilities in both the regulatory framework and the industry's highly concentrated supply chain, leading to legislative and regulatory responses.

Legal Authority

• 21 U.S.C. § 350a — Federal Food, Drug, and Cosmetic Act § 412 (Infant Formula Act of 1980, as amended): authorizes FDA to establish nutrient requirements for infant formulas; requires pre-market notification for new formulas; grants recall authority; requires quality control testing records and notification of manufacturing defects
• 21 U.S.C. § 321 — FDCA definitions; defines "food" and the adulteration and misbranding standards applicable to infant formula
• 21 CFR Part 107 — FDA regulations implementing the Infant Formula Act; specifies required nutrients, minimum and maximum levels, labeling requirements, quality factor testing, and recall procedures

Key Mechanics

Infant formula regulation under Part 107 combines mandatory nutrient standards with pre-market notification and manufacturing quality requirements. Every infant formula must contain at least 29 specified nutrients at minimum levels (and below maximum levels where specified) — the nutritional completeness requirement unique to infant formula. Manufacturers of new formulas (including significant changes to existing formulas) must notify FDA at least 90 days before marketing, providing detailed formula composition and safety/nutritional adequacy data. Manufacturers must test each batch for nutrient content before distribution; records must be retained for 2 years. A recall must be initiated when a formula fails to meet nutritional requirements or is contaminated — FDA has mandatory recall authority under § 350a(f).

Current Rule (2026)

What This Rule Does

The Infant Formula Act reflects a fundamental regulatory judgment: because infants cannot compensate for an inadequate diet (they cannot eat more foods, supplement, or otherwise self-correct), the government must ensure formula is nutritionally complete before it reaches the market. The statute and Part 107 create three tiers of requirements: nutritional standards (what must be in the formula and in what amounts), labeling requirements (how to communicate the formula's contents and use to caregivers), and recall and reporting requirements (what happens when a formula is found to be unsafe).

FDA's pre-market notification requirement — manufacturers must notify FDA at least 90 days before introducing a new formula or a significant reformulation — gives FDA an opportunity to review whether the formula meets nutrient specifications and to request additional testing. Manufacturers must submit a notification that includes the formula's nutrient content, quality control procedures, and the results of required laboratory analyses. Unlike drug approvals, FDA does not "approve" infant formulas in advance; the notification system is a review opportunity, not a licensing requirement. However, marketing a new formula without filing the required notification is itself an FDCA violation.

The 2022 Abbott manufacturing failures led to a recognition that FDA's existing framework had gaps: there were no mandatory testing requirements specifying how often manufacturers must test for specific pathogens, how to validate environmental monitoring for Cronobacter, or what manufacturing deviations trigger mandatory FDA notification. The 2024 final rule (89 FR 24082) filled several of these gaps, adding mandatory environmental monitoring requirements for Cronobacter sakazakii at powdered formula facilities, new manufacturing deviations reporting obligations, and enhanced qualification testing requirements for new formula batches.

Key Provisions

• § 107.3 — Definitions: "infant formula" — food which purports to be or is represented for special dietary use solely as a food for infants by reason of its simulation of human milk or its suitability as a complete or partial substitute for human milk; "exempt infant formula" — formula manufactured for infants with inborn errors of metabolism, low birth weight, or unusual medical or dietary problems (exempt from standard nutrient requirements because the patient's condition requires deviation from normal nutrient levels; must be under physician supervision); "infant" — a person not more than 12 months old
• § 107.10 — Nutrient information labeling: infant formula labels must state the quantity of each nutrient in the formula, expressed per 100 kilocalories; the order of nutrients must follow the regulatory sequence; the nutrient information must be conspicuous and clear enough for a caregiver to understand the composition; the nutrient disclosure requirement is distinct from the Nutrition Facts panel required for conventional foods — infant formula uses a "Nutrition Information" format that FDA prescribed by regulation in the 1980s and updates periodically
• § 107.20 — Directions for use: labels must include complete preparation instructions — dilution ratios for concentrated and powder formulas, mixing instructions, safe water temperature, refrigeration requirements for prepared formula, and the maximum time prepared formula may be kept; directions must be provided in English and may be required in additional languages for products marketed to populations with significant non-English speakers; the directions must be sufficient that a caregiver following them exactly would prepare and store formula safely
• § 107.30 — Exemptions for multiunit packaging: individual containers of ready-to-feed formula within a multiunit retail package (a case of 24 bottles, for example) are exempt from certain redundant labeling requirements if the outer package bears all required information
• § 107.50 — Terms and conditions for exempt formulas: formulas for infants with metabolic diseases (phenylketonuria, galactosemia, etc.) are exempt from the standard nutrient minimums because those minimums would harm the patient; the exemption applies only when the formula is specifically represented as appropriate only for infants with a specific inborn error of metabolism and is to be used under physician supervision; manufacturers of exempt formulas must still notify FDA before marketing and comply with quality control requirements
• § 107.100 — Nutrient specifications: the table of required nutrients establishes both minimum and maximum levels for each of 29 nutrients per 100 kcal of formula; required nutrients include protein, fat, linoleic acid, vitamins A, D, E, K, C, B1, B2, B3, B6, B12, folic acid, pantothenic acid, biotin, choline, inositol, calcium, phosphorus, magnesium, zinc, manganese, copper, iodine, selenium, sodium, potassium, and chloride; the minimum levels are based on evidence of nutritional sufficiency in healthy infants; the maximum levels are based on evidence of safe upper limits; FDA may update the nutrient table by rulemaking as scientific evidence evolves — the 2024 rule added new requirements based on updated DRI (Dietary Reference Intake) evidence for iodine and choline
• § 107.200 — FDA-required recall: when FDA determines that an adulterated or misbranded infant formula presents a risk to human health, it may require the manufacturer to conduct a recall; the mandatory recall authority (added by the 1986 FDCA amendments) is rare for most food categories but applies specifically to infant formula; FDA's determination may be based on microbiological testing (positive Cronobacter or Salmonella), nutrient deficiency or excess, foreign object contamination, or misbranding that could lead to incorrect preparation
• § 107.210 — Firm-initiated recalls: if a manufacturer voluntarily recalls an infant formula — for any reason, including concerns that don't meet the threshold for mandatory FDA action — the manufacturer must comply with the same notification and conduct requirements as for a mandatory recall; voluntary recalls account for most infant formula market withdrawals
• §§ 107.220–107.260 — Recall conduct requirements: the recalling firm must (1) evaluate the hazard in writing; (2) issue press releases to all relevant media outlets in the recall area; (3) notify consignees (distributors, retailers, hospitals) by telephone within 24 hours; (4) provide written confirmation to all consignees within 3 days; (5) submit periodic status reports to FDA on the scope and effectiveness of the recall; (6) provide a recommendation for termination when the hazard has been addressed; the recall must continue until FDA concurs it is complete; the completeness standard is high — a recall effective enough to remove substantially all distributed product from commerce
• § 107.280 — Records retention: manufacturers must maintain complete records of the distribution of every lot of infant formula — which lots went to which distributors, in what quantities, on what dates — for the useful life of the product plus one year; these records are the essential tool for recall effectiveness calculation; without them, it is impossible to know how many units of a recalled lot remain in commerce

How It Affects You

If you are a parent or caregiver: Part 107 is the regulatory guarantee that any infant formula legally sold in the United States contains at a minimum the 29 nutrients specified at the required levels. An infant formula on a U.S. retailer's shelf cannot legally be sold with nutrient levels below the Part 107 minimums. The recall provisions mean that when a formula is found to be unsafe, FDA can require the manufacturer to pull all product from commerce and notify every retailer and distributor in the supply chain. During the 2022 shortage, FDA set up an exemption system to allow imports of foreign formulas that met equivalent nutrient standards — demonstrating that the regulatory framework can be adapted under emergency conditions.

If you are a manufacturer of infant formula: FDA's pre-market notification requirement (90 days before marketing a new formula or significant reformulation) is a compliance threshold that affects product development timelines. The 2024 manufacturing requirements add mandatory environmental monitoring for Cronobacter at powdered formula facilities — you must have documented monitoring protocols, testing frequencies, and corrective action procedures in place. Manufacturing deviations — significant departures from your validated process — must now be reported to FDA within specified timeframes. The records retention requirement (distribution records for every lot) is a supply chain data infrastructure requirement: you need traceability systems sufficient to calculate recall effectiveness at the lot level.

If you are a hospital, WIC program, or institutional buyer: infant formula purchased for use in hospitals and WIC programs is subject to the same federal requirements as retail formula. WIC formularies are governed by state WIC agencies' sole-source contracts with formula manufacturers — contracts that give manufacturers significant market leverage in exchange for substantial discounts. The 2022 shortage demonstrated how sole-source contracting, combined with manufacturing concentration, can create supply vulnerability; WIC programs in 2022 were disproportionately affected because WIC beneficiaries had fewer substitution options when the contracted formula was recalled.

Statutory Authority

This rule implements:

• 21 U.S.C. § 350a — FDCA § 412 (Infant Formula Act of 1980, amended 1986) — the core statutory authority requiring FDA to establish nutrient requirements, pre-market notification, and recall authority for infant formula
• 21 U.S.C. § 321(z) — FDCA § 201(z) — the statutory definition of "infant formula" that establishes what products are subject to this regulatory regime
• 21 U.S.C. § 374 — Factory inspection authority — FDA authority to inspect infant formula manufacturing facilities, which it exercises more frequently and thoroughly than for conventional food facilities

Recent Rulemakings

• 89 FR 24082 (April 2024) — major rule adding mandatory environmental monitoring for Cronobacter sakazakii at powdered formula facilities, new manufacturing deviation notification requirements, and enhanced qualification testing for new formula batches; the rule was the regulatory response to the 2022 Abbott recall and shortage
• 76 FR 18511 (April 2011) — update to nutrient content requirements based on Dietary Reference Intakes; revised minimum and maximum levels for several nutrients including iodine and choline
• Original Infant Formula Act regulations: 51 FR 20072 (June 3, 1986) — original Part 107 rulemaking implementing the Infant Formula Act requirements, including the nutrient specification table, labeling requirements, and mandatory recall authority

Pending Action